Proniras Corporation is a preclinical-stage biotech company focused on development of a new parenteral medical countermeasure (MCM) to treat seizures and brain injury that occurs following exposure to organophosphorus nerve agents.
Location: United States, Washington, Seattle
Employees: 1-10
Total raised: $89.5M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | WRF Capita... | wrfseattle... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.04.2018 | - | $89.5M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 01.02.2024 | Proniras Secures $4.65 in Series B Financing | Proniras, a Seattle, WA-based clinical-stage biotechnology company developing novel small-molecule t... | finsmes.co... |
| 27.04.2018 | Proniras launches with BARDA funding to pit migraine drug ag... | Accelerator Life Science Partners launched a spinoff company to develop an investigational migraine ... | fiercebiot... |
| 27.04.2018 | Proniras Corp. launches in Seattle, scores $89.5 million con... | Chris Toombs, Proniras co-founder and chief scientific officer. (Accelerator Life Science Partners P... | geekwire.c... |
| 27.04.2018 | Proniras launches with BARDA funding to pit migraine drug ag... | Accelerator Life Science Partners launched a spinoff company to develop an investigational migraine ... | fiercebiot... |
| - | Proniras Corp | “Proniras” | fastfounde... |